Comprehensive Stock Comparison
Compare Exelixis, Inc. (EXEL) vs CG Oncology, Inc. Common stock (CGON) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | CGON | 458.3% revenue growth vs EXEL's 7.0% |
| Quality / Margins | EXEL | 29.6% net margin vs CGON's -69.7% |
| Stability / Safety | EXEL | Beta 0.63 vs CGON's 1.55 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | CGON | +127.4% vs EXEL's +13.9% |
| Efficiency (ROA) | EXEL | 24.0% ROA vs CGON's -20.8%, ROIC 32.1% vs -26.3% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes targeted cancer therapies. It generates revenue primarily from sales of its flagship drug Cabometyx — which accounts for the vast majority of its revenue — along with royalties from partnered products like Cotellic. The company's competitive advantage lies in its deep expertise in tyrosine kinase inhibitors and its focused pipeline targeting difficult-to-treat cancers.
CG Oncology is a clinical-stage biopharmaceutical company developing novel immunotherapies for bladder cancer. It currently generates no revenue from product sales—its business model depends on advancing its lead candidate, cretostimogene, through clinical trials toward regulatory approval and future commercialization. The company's potential moat lies in its oncolytic immunotherapy platform targeting BCG-unresponsive bladder cancer—a high-unmet-need area with limited treatment options.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
EXEL leads in 3 of 6 categories (Financial Metrics, Profitability & Efficiency). CGON leads in 1 (Valuation Metrics). 1 tied.
Financial Metrics (TTM)
EXEL is the larger business by revenue, generating $2.3B annually — 1052.5x CGON's $2M. EXEL is the more profitable business, keeping 29.6% of every revenue dollar as net income compared to CGON's -69.7%. On growth, CGON holds the edge at +37.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | EXELExelixis, Inc. | CGONCG Oncology, Inc.… |
|---|---|---|
| RevenueTrailing 12 months | $2.3B | $2M |
| EBITDAEarnings before interest/tax | $830M | -$180M |
| Net IncomeAfter-tax profit | $678M | -$151M |
| Free Cash FlowCash after capex | $753M | -$117M |
| Gross MarginGross profit ÷ Revenue | +96.6% | +20.3% |
| Operating MarginEBIT ÷ Revenue | +35.0% | -82.9% |
| Net MarginNet income ÷ Revenue | +29.6% | -69.7% |
| FCF MarginFCF ÷ Revenue | +32.9% | -53.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +10.8% | +37.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +75.0% | -90.0% |
Valuation Metrics
| Metric | EXELExelixis, Inc. | CGONCG Oncology, Inc.… |
|---|---|---|
| Market CapShares × price | $11.8B | $4.6B |
| Enterprise ValueMkt cap + debt − cash | $11.5B | $4.3B |
| Trailing P/EPrice ÷ TTM EPS | 15.85x | -41.70x |
| Forward P/EPrice ÷ next-FY EPS est. | 13.29x | — |
| PEG RatioP/E ÷ EPS growth rate | 0.31x | — |
| EV / EBITDAEnterprise value multiple | 13.19x | — |
| Price / SalesMarket cap ÷ Revenue | 5.09x | 4041.01x |
| Price / BookPrice ÷ Book value/share | 5.75x | 5.01x |
| Price / FCFMarket cap ÷ FCF | 13.36x | — |
Profitability & Efficiency
EXEL delivers a 31.4% return on equity — every $100 of shareholder capital generates $31 in annual profit, vs $-22 for CGON. CGON carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to EXEL's 0.08x. On the Piotroski fundamental quality scale (0–9), EXEL scores 7/9 vs CGON's 6/9, reflecting strong financial health.
| Metric | EXELExelixis, Inc. | CGONCG Oncology, Inc.… |
|---|---|---|
| ROE (TTM)Return on equity | +31.4% | -22.0% |
| ROA (TTM)Return on assets | +24.0% | -20.8% |
| ROICReturn on invested capital | +32.1% | -26.3% |
| ROCEReturn on capital employed | +35.0% | -25.0% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 6 |
| Debt / EquityFinancial leverage | 0.08x | 0.00x |
| Net DebtTotal debt minus cash | -$309M | -$257M |
| Cash & Equiv.Liquid assets | $482M | $257M |
| Total DebtShort + long-term debt | $173M | $238,000 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Total Returns (with DRIP)
A $10,000 investment in EXEL five years ago would be worth $19,758 today (with dividends reinvested), compared to $15,819 for CGON. Over the past 12 months, CGON leads with a +127.4% total return vs EXEL's +13.9%. The 3-year compound annual growth rate (CAGR) favors EXEL at 37.1% vs CGON's 16.5% — a key indicator of consistent wealth creation.
| Metric | EXELExelixis, Inc. | CGONCG Oncology, Inc.… |
|---|---|---|
| YTD ReturnYear-to-date | +1.1% | +40.7% |
| 1-Year ReturnPast 12 months | +13.9% | +127.4% |
| 3-Year ReturnCumulative with dividends | +158.0% | +58.2% |
| 5-Year ReturnCumulative with dividends | +97.6% | +58.2% |
| 10-Year ReturnCumulative with dividends | +1110.4% | +58.2% |
| CAGR (3Y)Annualised 3-year return | +37.1% | +16.5% |
Risk & Volatility
EXEL is the less volatile stock with a 0.63 beta — it tends to amplify market swings less than CGON's 1.55 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CGON currently trades 98.0% from its 52-week high vs EXEL's 88.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | EXELExelixis, Inc. | CGONCG Oncology, Inc.… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.63x | 1.55x |
| 52-Week HighHighest price in past year | $49.62 | $60.00 |
| 52-Week LowLowest price in past year | $32.38 | $14.80 |
| % of 52W HighCurrent price vs 52-week peak | +88.8% | +98.0% |
| RSI (14)Momentum oscillator 0–100 | 53.1 | 58.2 |
| Avg Volume (50D)Average daily shares traded | 2.1M | 986K |
Analyst Outlook
Wall Street rates EXEL as "Buy" and CGON as "Buy". Consensus price targets imply 34.4% upside for CGON (target: $79) vs 0.8% for EXEL (target: $44).
| Metric | EXELExelixis, Inc. | CGONCG Oncology, Inc.… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $44.40 | $79.00 |
| # AnalystsCovering analysts | 32 | 9 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +8.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Feb 24 | Feb 26 | Change |
|---|---|---|---|
| Exelixis, Inc. (EXEL) | 100 | 196.83 | +96.8% |
| CG Oncology, Inc. C… (CGON) | 102.1 | 146.19 | +43.2% |
Exelixis, Inc. (EXEL) returned +98% over 5 years vs CG Oncology, Inc. C… (CGON)'s +58%. A $10,000 investment in EXEL 5 years ago would be worth $19,758 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Exelixis, Inc. (EXEL) | $191M | $2.3B | +1111.8% |
| CG Oncology, Inc. C… (CGON) | $10M | $1M | -89.0% |
Exelixis, Inc.'s revenue grew from $191M (2016) to $2.3B (2025) — a 31.9% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Exelixis, Inc. (EXEL) | -36.7% | 33.7% | +192.0% |
| CG Oncology, Inc. C… (CGON) | -124.0% | -77.3% | +37.6% |
Exelixis, Inc.'s net margin went from -37% (2016) to 34% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Exelixis, Inc. (EXEL) | 62 | 15.8 | -74.5% |
Exelixis, Inc. has traded in a 9x–62x P/E range over 9 years; current trailing P/E is ~16x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Exelixis, Inc. (EXEL) | -0.28 | 2.78 | +1092.9% |
| CG Oncology, Inc. C… (CGON) | -0.28 | -1.41 | -403.6% |
Exelixis, Inc.'s EPS grew from $-0.28 (2016) to $2.78 (2025).
Chart 6Free Cash Flow — 5 Years
Exelixis, Inc. generated $884M FCF in 2025 (+163% vs 2021). CG Oncology, Inc. Common stock generated $-79M FCF in 2024 (-474% vs 2021).
EXEL vs CGON: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is EXEL or CGON a better buy right now?
Exelixis, Inc. (EXEL) offers the better valuation at 15.8x trailing P/E (13.3x forward), making it the more compelling value choice. Analysts rate Exelixis, Inc. (EXEL) a "Buy" — based on 32 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — EXEL or CGON?
Over the past 5 years, Exelixis, Inc. (EXEL) delivered a total return of +97.6%, compared to +58.2% for CG Oncology, Inc. Common stock (CGON). A $10,000 investment in EXEL five years ago would be worth approximately $20K today (assuming dividends reinvested). Over 10 years, the gap is even starker: EXEL returned +1110% versus CGON's +58.2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — EXEL or CGON?
By beta (market sensitivity over 5 years), Exelixis, Inc. (EXEL) is the lower-risk stock at 0.63β versus CG Oncology, Inc. Common stock's 1.55β — meaning CGON is approximately 148% more volatile than EXEL relative to the S&P 500. On balance sheet safety, CG Oncology, Inc. Common stock (CGON) carries a lower debt/equity ratio of 0% versus 8% for Exelixis, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — EXEL or CGON?
Exelixis, Inc. (EXEL) is the more profitable company, earning 33.7% net margin versus -77.3% for CG Oncology, Inc. Common stock — meaning it keeps 33.7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EXEL leads at 37.6% versus -100.7% for CGON. At the gross margin level — before operating expenses — CGON leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is EXEL or CGON more undervalued right now?
Analyst consensus price targets imply the most upside for CGON: 34.4% to $79.00.
06Which pays a better dividend — EXEL or CGON?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is EXEL or CGON better for a retirement portfolio?
For long-horizon retirement investors, Exelixis, Inc. (EXEL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.63), +1110% 10Y return). CG Oncology, Inc. Common stock (CGON) carries a higher beta of 1.55 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EXEL: +1110%, CGON: +58.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between EXEL and CGON?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: EXEL is a mid-cap deep-value stock; CGON is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.